|
Play Video: The Importance of Insider Buying
|
|
|
The table below summarizes the most recent OncoCyte insider buying information, with links below the price to see the
CAGR achieved by each insider on their purchases. As the saying goes on Wall St., there are many
possible reasons to sell a stock, but only one reason to buy. Watch the importance of insider buying video for more
information about why OncoCyte insider buys are important for investors to follow.
Date | Insider | Price | Amount |
4-11-2024 Insider Buy |
BROADWOOD PARTNERS, L.P. >10% Owner |
$2.92
CAGR »
|
$7,057,688.00 2,420,000 shares |
4-11-2024 Insider Buy |
Andrew Arno Director |
$2.95
CAGR »
|
$99,999.10 33,898 shares |
4-11-2024 Insider Buy |
Josh Riggs CEO and President |
$2.95
CAGR »
|
$10,000.50 3,390 shares |
6-14-2023 Insider Buy |
Alfred D. Kingsley Director |
$0.21
CAGR »
|
$6,447.00 30,000 shares |
4-3-2023 Insider Buy |
BROADWOOD PARTNERS, L.P. >10% Owner |
$0.30
CAGR »
|
$8,093,898.38 26,827,638 shares |
12-23-2022 Insider Buy |
John Peter Gutfreund Director |
$0.33
CAGR »
|
$24,727.50 75,000 shares |
12-23-2022 Insider Buy |
Andrew Arno Director |
$0.35
CAGR »
|
$87,875.00 250,000 shares |
12-22-2022 Insider Buy |
Alfred D. Kingsley Director |
$0.28
CAGR »
|
$7,125.00 25,000 shares |
8-17-2022 Insider Buy |
Andrew Arno Director |
$0.90
CAGR »
|
$13,500.00 15,000 shares |
8-17-2022 Insider Buy |
Andrew J. Last Director |
$0.87
CAGR »
|
$17,400.00 20,000 shares |
8-16-2022 Insider Buy |
Ronald Asbury Andrews President & CEO |
$0.96
CAGR »
|
$38,400.00 40,000 shares |
8-16-2022 Insider Buy |
Jennifer L. Carter Director |
$0.95
CAGR »
|
$9,975.00 10,500 shares |
8-16-2022 Insider Buy |
Melinda Griffith Director |
$1.00
CAGR »
|
$10,000.00 10,000 shares |
8-15-2022 Insider Buy |
John Peter Gutfreund Director |
$0.93
CAGR »
|
$23,250.00 25,000 shares |
8-15-2022 Insider Buy |
Alfred D. Kingsley Director |
$0.97
CAGR »
|
$9,700.00 10,000 shares |
8-16-2022 Insider Buy |
Andrew Arno Director |
$0.96
CAGR »
|
$144,120.92 150,000 shares |
4-14-2022 Insider Buy |
BROADWOOD PARTNERS, L.P. >10% Owner |
$1.33
CAGR »
|
$7,999,999.54 6,003,752 shares |
3-25-2022 Insider Buy |
Douglas T. Ross Chief Scientific Officer |
$1.40
CAGR »
|
$21,000.00 15,000 shares |
3-16-2022 Insider Buy |
Ronald Asbury Andrews Chief Executive Officer |
$1.28
CAGR »
|
$64,150.00 50,000 shares |
3-17-2022 Insider Buy |
Gisela Paulsen Chief Operating Officer |
$1.20
CAGR »
|
$19,767.00 16,500 shares |
3-16-2022 Insider Buy |
Cavan M. Redmond Director |
$1.19
CAGR »
|
$47,560.00 40,000 shares |
2-5-2021 Insider Buy |
BROADWOOD PARTNERS, L.P. >10% Owner |
$4.50
CAGR »
|
$2,700,000.00 600,000 shares |
3-19-2021 Insider Buy |
Ronald Asbury Andrews Chief Executive Officer |
$4.79
CAGR »
|
$52,702.10 11,000 shares |
9-12-2020 Insider Buy |
Mitchell S. Levine CFO |
$2.01
CAGR »
|
$20,060.00 10,000 shares |
8-3-2020 Insider Buy |
Tony T. Kalajian Sr.VP/Chief Accounting Officer |
$1.31
CAGR »
|
$6,533.00 5,000 shares |
8-3-2020 Insider Buy |
Albert P. Parker Chief Operating Officer |
$1.33
CAGR »
|
$6,648.00 5,000 shares |
4-24-2020 Insider Buy |
BROADWOOD PARTNERS, L.P. >10% Owner |
$2.27
CAGR »
|
$2,383,500.00 1,050,000 shares |
3-31-2020 Insider Buy |
Ronald Asbury Andrews CEO and President |
$2.30
CAGR »
|
$104,149.73 45,216 shares |
1-2-2020 Insider Buy |
BROADWOOD PARTNERS, L.P. >10% Owner |
$2.16
CAGR »
|
$3,000,000.70 1,391,466 shares |
11-13-2019 Insider Buy |
BROADWOOD PARTNERS, L.P. >10% Owner |
$1.70
CAGR »
|
$2,000,000.70 1,176,471 shares |
9-13-2019 Insider Buy |
Tony T. Kalajian SVP-Chief Accounting Officer |
$1.98
CAGR »
|
$19,800.00 10,000 shares |
9-11-2019 Insider Buy |
BROADWOOD PARTNERS, L.P. >10% Owner |
$1.66
CAGR »
|
$3,320,000.00 2,000,000 shares |
3-28-2018 Insider Buy |
BROADWOOD PARTNERS, L.P. >10% Owner |
$1.26
CAGR »
|
$5,000,000.04 3,968,254 shares |
Also See: Institutional Holders of OCX
Also See: SEC filings
Below we present the annualized performance delivered by OncoCyte stock since 4-11-2024 (the date of the most recent
insider purchase). The performance of the investment from the time OncoCyte insider buying occurred is the ultimate
test of whether insiders were right about OCX being a good buy.
Growth of $10,000.00
Without Dividends Reinvested
|
Start date: |
04/12/2024 |
|
End date: |
04/26/2024 |
|
Start price/share: |
$2.71 |
|
End price/share: |
$2.48 |
|
Dividends collected/share: |
$0.00 |
|
Total return: |
-8.49% |
|
Annualized Gain: |
-221.27% |
|
Starting investment: |
$10,000.00 |
|
Ending investment: |
$9,151.00 |
|
Years: |
0.04 |
|
OncoCyte Insider Buying
This Holdings Channel page has presented insider buying activity, covering Directors, officers (such as CEO, CFO, COO, etc.),
and >10% owners (who are required to file form 4's with the SEC). Important institutional owners may not fall under these
categories, but instead file their holdings quarterly on the latest form 13F filings.
While recent OncoCyte insider buying activity is included, there may also be stock sales over this same period (Also See: SEC filings for sales and other details).
Also See: Funds Holding OCX
|
|